TY - JOUR
T1 - Candidate vaccines for human Rift Valley fever
AU - Ikegami, Tetsuro
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/12/2
Y1 - 2019/12/2
N2 - Introduction: Rift Valley fever (RVF) outbreaks can cause devastating economic loss and public health concerns. RVF virus (RVFV: genus Phlebovirus family Phenuiviridae) is transmitted by mosquitoes, causes abortion in sheep, cattle, and goats, and severe diseases in humans including hemorrhagic fever, encephalitis, or retinitis. RVFV has spread from sub-Saharan Africa into Madagascar, Egypt, Saudi Arabia, and Yemen. Area covered: There are a few licensed veterinary RVF vaccines in endemic countries, whereas no licensed RVF vaccines are available for human use. There are two Investigational New Drug (IND) RVF candidate vaccines used in clinical trials. This review will discuss the development of two IND vaccines for RVF over the past 20–40 years, and further innovation for future RVF vaccines applicable for the use in endemic areas. Expert opinion: Vaccination for human RVF can protect at-risk personnel against severe RVF illness. Formalin-inactivated RVF candidate vaccine requires three doses to induce protective immunity, whereas the live-attenuated MP-12 candidate vaccine retains strong immunogenicity. Further innovation in safety, immunogenicity, and thermostability will facilitate future RVF vaccines for humans.
AB - Introduction: Rift Valley fever (RVF) outbreaks can cause devastating economic loss and public health concerns. RVF virus (RVFV: genus Phlebovirus family Phenuiviridae) is transmitted by mosquitoes, causes abortion in sheep, cattle, and goats, and severe diseases in humans including hemorrhagic fever, encephalitis, or retinitis. RVFV has spread from sub-Saharan Africa into Madagascar, Egypt, Saudi Arabia, and Yemen. Area covered: There are a few licensed veterinary RVF vaccines in endemic countries, whereas no licensed RVF vaccines are available for human use. There are two Investigational New Drug (IND) RVF candidate vaccines used in clinical trials. This review will discuss the development of two IND vaccines for RVF over the past 20–40 years, and further innovation for future RVF vaccines applicable for the use in endemic areas. Expert opinion: Vaccination for human RVF can protect at-risk personnel against severe RVF illness. Formalin-inactivated RVF candidate vaccine requires three doses to induce protective immunity, whereas the live-attenuated MP-12 candidate vaccine retains strong immunogenicity. Further innovation in safety, immunogenicity, and thermostability will facilitate future RVF vaccines for humans.
KW - Clinical trial
KW - Investigational New Drug
KW - Rift Valley fever
KW - thermostability
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85071981923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071981923&partnerID=8YFLogxK
U2 - 10.1080/14712598.2019.1662784
DO - 10.1080/14712598.2019.1662784
M3 - Review article
C2 - 31478397
AN - SCOPUS:85071981923
SN - 1471-2598
VL - 19
SP - 1333
EP - 1342
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 12
ER -